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Introduction: Our objective was to find out if there are antibodies binding to homocitrulline-containing type I and
II collagen carboxyterminal telopeptides in sera of patients with rheumatoid arthritis (RA), and if these antibodies
cross-react with citrulline and homocitrulline in the same peptide sequence.
Methods: A total of 72 RA and 72 control sera were analyzed for binding using enzyme-linked immunosorbent
assay to citrulline- or homocitrulline-containing type I and II collagen carboxyterminal telopeptides, as well as to
cyclic citrullinated peptide (CCP) and to mutated citrullinated vimentin (MCV). Specificities of the antibodies were
tested using inhibition-ELISA.
Results: Of the RA sera, 39 (54%) and 41 (57%) were positive for binding to CCP and MCV, respectively. Further, 34
(47%) and 30 (42%) of the patients had specific antibodies binding to and being inhibited by citrulline-containing
type I collagen telopeptides and by citrulline-containing type II collagen carboxyterminal telopeptides, respectively.
The corresponding figures regarding homocitrulline-containing type I and homocitrulline-containing type II collagen
telopeptides were 16 (22%) and 14 (19%). Most of the patients, who were seropositive for citrullinated peptides,
showed binding in multiple assays. A total of 10 (14%) RA patients were positive for all the tested peptide pairs,
while 28 (39%) of them had antibodies that contained overlapping specifities between citrulline and homocitrulline
in the same peptide sequence.
Conclusions: Antibodies to both citrulline and homocitrulline containing type I and II collagen telopeptides can be
found in sera of RA patients. These antibodies are not constant from one RA patient to another, but contain
separate or overlapping specificities within the same peptide sequence varying between individuals. Our results
suggest some relationship between citrulline and homocitrulline-recognizing antibodies, since homocitrulline
antibodies exist mainly in individuals seropositive to anti-CCP and anti-MCV.Introduction
The search for citrullinated antigens in patients with
rheumatoid arthritis (RA) has been in focus during recent
years. The identification of the original immunogen for
their production could be the key to the prevention of the
immune response and the consequent cascade of the* Correspondence: sanna.turunen@oulu.fi
1Department of Clinical Chemistry, Institute of Diagnostics, University of
Oulu, P.O. Box 5000, Oulu FI-90014, Finland
2Northern Laboratory Centre NordLab and Medical Research Centre, Oulu
University Hospital, Oulu, Finland
Full list of author information is available at the end of the article
© 2015 Turunen et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.inflammatory process leading to tissue damage and loss of
function. Antibodies against citrullinated proteins are a
frequent finding in RA patients and may precede the onset
of clinical symptoms by several years [1-3]. We have previ-
ously shown the presence of antibodies binding to citrulli-
nated type I and II collagen telopeptides in sera of RA
patients [4]. Several tests for antibodies binding to citrulli-
nated peptides have been developed and some are in clin-
ical use; however, they do not present the original antigen
but rather rely on the cross-reaction of anti-citrullinated
protein antibodies (ACPA). The presence of ACPA in the
sera, measured by the anti-cyclic citrullinated proteinl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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component of the American College of Rheumatology –
European League against Rheumatism (ACR – EULAR)
2010 classification criteria for RA [5]. Anti-CCP, however,
measures the binding of the sera to a mixture of several
citrullinated peptides. These peptides have been chosen to
give an optimal distinction between controls and patients
with RA [6]. Nevertheless, the presence of ACPA in RA
patient sera has been connected to poor prognosis and
erosive course of the disease.
Lately, also, the contingent effect of carbamylation on
the pathogenetic process of RA has become of interest.
Carbamylation through myeloperoxidase is part of a nat-
ural defense mechanism and takes place in inflammatory
conditions (reviewed in [7]), and has been proposed as a
link between smoking, uremia, inflammation and athero-
genesis [8]. The product of lysine carbamylation is homo-
citrulline, a structural homolog of citrulline. Recently
antibodies against both citrullinated and carbamylated an-
tigens were found to be present simultaneously in sera of
RA patients [9]. We have shown that a low amount of
homocitrulline can be present in RA tissues simultan-
eously with citrulline [10]. An interesting coexistence of
citrullination and myeloperoxidase activity is found at
least in neutrophil extracellular traps (NETs). NETs are
also present in periodontitis [11] and by containing citrul-
linated proteins they may be involved in ACPA formation
and trigger subsequent development of RA [12,13].
Altough ACPAs arise in RA patients years before the on-
set of clinical disease, the origin of these antibodies is not
known. The RA patients’ antibody repertoire has been re-
ported to go through epitope spreading between citrulli-
nated antigens [3,14,15]. The specificity of these antibodies
for citrulline-containing epitopes is certain. However, the
antibodies have been found to be of low avidity [16]. We
have demonstrated that antibodies against citrullinated pro-
teins can be developed by immunizing rabbits either with
citrullinated or carbamylated (homocitrulline-containing)
antigens [17]. Also, antibodies binding to homocitrulline-
containing fibrinogen have been detected in RA patients.
Furthermore, these were found to cross-react with similar
citrulline-containing sequences [18]. In this study, we shed
light on the RA patients’ antibody repertoire binding to
citrulline- and homocitrulline-containing peptides related
to type I and type II collagen carboxyterminal telopeptides.
The objective of this study is to define the binding proper-
ties of the antibodies binding to citrullinated proteins, not
to present another method for RA diagnosis.
Methods
Ethical considerations
The study was conducted according to the requirements
of the Declaration of Helsinki and was approved by the
ethics committee of the Central Hospital of Jyväskylä.All patients gave verbal informed consent before inclu-
sion in the study. In the 1980s, when the study was
designed and conducted, no Good Clinical Practice in-
structions existed. Verbal consent in clinical studies was
common praxis. The study design was accepted by the
ethics committee of the hospital.Subjects and controls
A total of 72 RA patients diagnosed in the years 1987 and
1988 in the Jyväskylä Central Hospital according to the
Ropes criteria (Ropes 1959), whose sera were available
were included in the present study [19]. At the baseline,
the patients were characterized as suffering either from
polyarticular (n = 53), oligoarticular (n = 8), palindromic
(n = 5) or polymyalgic (n = 6) disease. The cohort included
43 women, 24- to 75-years old (mean 49.1 years) and 29
men, 22- to 72-years old (mean 53.5 years). The erosion
status was assessed from 24 to 74 months after the diag-
nosis according to the method of Larsen et al. [20]. Sera
from 72 age and sex matched laboratory staff, non-RA hip
surgery patients and medical students were used as con-
trols. Positivity in anti-CCP or in anti-mutated citrulli-
nated vimentin (MCV) assays was used as an excluding
factor for the control population. The control sera were
collected during 2010 to 2013. All sera were kept at −20°C.
Preliminary testing of 38 hemodialysis patients was also
performed to exclude the possible effect of high serum
urea levels in antibody development (data not shown).Collagen telopeptide assays
All sera were tested by enzyme-linked immunosorbent
assay (ELISA) for binding of immunoglobulin G (IgG)
to citrullinated and homocitrullinated type I and II
collagen carboxyterminal telopeptides under standard
conditions, and the binding was inhibited by addition
of soluble antigens [21] to a final concentration of
100 μg/ml. The two biotinylated peptides correspond-
ing to the carboxyterminal telopeptide of the α1 chain
of human type I collagen (NeoMPS, Strasbourg, France)
represent amino acids 1193 to 1218, and the two bio-
tinylated peptides corresponding to the α 1 chain of
human type II collagen represent amino acids 1217 to
1241, counted from the amino-terminus in the pro α 1
chains of type I or type II procollagen, respectively.
The synthetic peptides that were used as inhibitors in
the ELISA represent the carboxyteminal ends of these
parent peptides. The peptide sequences are given in
Table 1. In each serum, the difference between bind-
ings with and without inhibition was calculated for all
peptide pairs. The patient results were divided into
positive and negative using cut-off values defined as
mean + 2 standard deviations (SD) of the control
group (Table 2).




SP112 biotin SAG FDF SFL PQP PQE KAH DGG RYY Cit A CitI
SP132 biotin SAG FDF SFL PQP PQE KAH DGG RYY Hcit A HcitI
SP66 – –- –- –- –E KAH DGG RYY Cit A CitI
SP135 – –- –- –- –E KAH DGG RYY Hcit A HcitI
Type II
collagen
SP86 biotin GID MSA FAG LGP REK GPD PLQ YM Cit A CitII
SP109 biotin GID MSA FAG LGP REK GPD PLQ YM Hcit A HcitII
SP41 — –- –- –- -EK GPD PLQ YM Cit A CitII
SP136 — –- –- –- -EK GPD PLQ YM Hcit A HcitII
The peptides represent different parts of the carboxy-terminal telopeptide of the
α1 chain of human type I or II collagen, each containing citrulline (Cit) or
homocitrulline (Hcit) as indicated (for other amino acids, the one-letter symbols
are used).
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Anti-CCP (Immunoscan RA (Mark 2) from Euro
Diagnostica, Malmö, Sweden) and anti-MCV (ORG
546, from ORGANTEC Diagnostica GmbH, Mainz,
Germany) assays were performed according to the
manufacturers’ instructions. All control and patient
sera were tested in duplicate.
Statistical methods
All 72 control sera included were negative for anti-CCP
(<25 U/ml) and anti-MCV (<20 U/ml). Logistic regression
analysis was used for evaluation of the association of each
test or test type (citrulline or homocitrulline tests) with bone
erosions in RA patients (IBM Corp. Released 2010. IBM
SPSS Statistics for Windows, Version 19.0. Armonk, NY,
USA). Differences were considered significant at P <0.01.
Results
Patients with RA were found to have antibodies that
bind to citrulline and homocitrulline-containing se-
quences related to type I and II collagen telopeptides
(Figures 1 and 2). These antibodies were rare in healthyTable 2 Sensitivity and specificity of citrulline and
homocitrulline inhibition-ELISA assays for separating RA








aPositivity in CCP or MCV was considered as excluding factor in controls.
Anti-CCP, anti-cyclic citrullinated protein; anti-MCV, anti-mutated citrullinated
vimentin; Cit, citrulline; Hcit, homocitrulline.individuals (4% to 5% of the controls) and in hemo-
dialysis patients (data not shown). The differences be-
tween patients and controls were statistically significant
for all assays (Table 3).
We measured specific antibodies to citrullinated type I
collagen-related peptides using inhibition ELISA, where
similar peptides were used both for binding the serum
antibodies and in smaller, soluble form also to inhibit
the binding. We found CitI specific antibodies in 34
(47%) of the 72 patient sera, while 16 (22%), 30 (42%)
and 14 (19%) of the sera contained antibodies specific
for HcitI, CitII and HcitII sequences, respectively. Fur-
thermore, a total of 39 (54%) and 41 (57%) of the patient
sera bound the respective antigens in direct ELISA for
anti-CCP and anti-MCV. Total ELISA data can be found
in Additional file 1.
Most of the sera that bound citrullinated peptides were
reactive in multiple assays. A total of 10 (14%) sera
contained specific antibodies to all four peptide pairs.
Moreover, 28 (39%) of the patients had antibodies with
overlapping specificities, so that the binding could be
inhibited by peptides with different ureido group-
containing amino acids. Of these, 16 (22%) sera showed
such binding to citrulline-containing peptide that could
be inhibited by homocitrulline-containing peptide. For
another 16 (22%) sera the binding to homocitrulline-
containing peptide could be inhibited by the correspond-
ing citrulline-containing peptide. In only four (6%) of
the cases were the antibodies cross-reactive and could
be inhibited simultaneously in both directions.
We could analyze sera taken at two different time
points from 19 patients (data not shown). There was
only slight variation in the titers of antibodies to specific
collagen telopeptide sequences between the two samples.
We also preliminarily tested sera from 38 hemodialysis
patients for binding to citrulline- and homocitrulline-
containing peptides to exclude a possible effect of high
serum urea levels and found the results comparable to
those of healthy controls.
Logistic regression analysis
The association of the results of each inhibition-ELISA
to erosive disease was assessed using logistic regression
analysis (Table 3). MCV had the strongest association to
the development of erosions with an odds ratio (OR) of
15.6. CCP also was well associated to erosions, with an
OR of 8, but it gave no additional value when combined
with MCV. As expected, rheumatoid factor (RF) was
also well associated with erosions with an OR of 7. The
presence of antibodies to the collagen-related antigens
CitI (OR 2.8; P = 0.043), CitII (OR 3.6; P = 0.016) and
HcitII (OR 5.2; P = 0.042) reached close to statistically
significant association with erosive RA, whereas for anti-
bodies against HcitI (OR 2.4; P = 0.171) the association
Figure 1 Illustration of the specific binding (inhibition-%) in RA patients (n = 72) and in controls (n = 72). Mean is shown as a solid line
and ± 2SD is shown by dotted lines. For abbreviations, see Table 1. RA, rheumatoid arthritis; SD, standard deviation.
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of joint erosions was checked against the presence of
antibodies to either CitI or CitII in patient sera, the OR
was 3.6 (P = 0.012), comparable to that of the combined
homocitrulline tests; if a patient serum contained either
HcitI or HcitII antibodies, the OR for erosions was 3.7
(P = 0.037).
Discussion
We have previously obtained results in rabbit experiments
indicating that antibodies against citrullinated antigens
can also be induced with homocitrulline-containingFigure 2 Overview of the antibody specifities in controls (panels A an
MCV results. In panels A and B, antibodies specific to CitI are depicted in
In panels C and D, antibodies to CitII are presented in dark columns/blue a
percent of inhibition by respective soluble peptides to binding to the simil
to the antigens of the CCP and MCV assays, shown as arbitrary units define
Hcit, homocitrulline; MCV, mutated citrullinated vimentin; RA, rheumatoid aimmunogens [17] and that homocitrulline can be present
in human RA tissue together with citrulline [10]. In this
study, we wanted to define properties of RA antibodies
that bind to citrulline- and homocitrulline-containing
epitopes.
The antibodies binding to citrullinated and carbamy-
lated proteins are induced even years prior to clinical
RA onset [2,22]. The development is characterized by
epitope spreading between antigens and the fine-tuning
of the specificity of these antibodies [3,14]. Furthermore,
in established disease the antibody repertoire remains
fairly stabile [23]. The same phenomenon was also seend C) and RA patients (panels B and D) and RA patients’ CCP and
dark columns/blue and those specific for HcitI in light columns/green.
nd those to HcitII in light column/green. The values shown are
ar immobilized peptide. Panel E shows the binding of RA patient sera
d by each manufacturer. CCP, cyclic citrullinated protein; Cit, citrulline;
rthritis.
Table 3 Logistic regression analysis of the association of
different antibody detection methods to erosions in RA
patients
Test OR 95% CI P
Anti-CCP 8.455 2.82 to 25.34 <0.001
Anti-MCV 15.583 4.76 to 51.05 <0.001
RF 7.506 2.54 to 22.20 <0.001
CitI 2.815 1.03 to 7.66 0.043
CitII 3.632 1.27 to 10.37 0.016
CitI or CitII 3.600 1.32 to 9.83 0.012
HcitI 2.400 0.69 to 8.40 0.171
HcitII 5.200 1.06 to 25.41 0.042
HcitI or Hcit II 3.692 1.08 to 12.61 0.037
CCP, cyclic citrullinated protein; CI, confidence interval; Cit, citrulline; Hcit,
homocitrulline; MCV, mutated citrullinated vimentin; OR, odds ratio; RA,
rheumatoid arthritis; RF, rheumatoid factor.
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containing collagen telopeptides.
We found that RA patients had specific antibodies to
the CitI, CitII, HcitI and HcitII antigens. The antibodies
binding to citrulline- or homocitrulline-containing telo-
peptides could be detected separately or simultaneously
in the same serum. Evidently the antibodies present in
sera of RA patients were able to discern between citrul-
line and homocitrulline in the same peptide-sequence,
although there were also some overlapping specificities.
The overlapping specificities were shown as the sera
were able to bind to a citrullinated antigen, but could be
inhibited by a soluble homocitrullinated peptide or vice
versa. This phenomenon was usually detected only in
one direction in a particular serum sample, but in two of
the sera there was a cross-reaction in both directions
(Additional file 1, inhibition table of all patients).
As we analyzed the two different serum samples of the
same patient, the presence of antibodies to homocitrulline-
containing antigens was found to be quite a constant
phenomenon, in line with that of ACPAs. Once anti-
homocitrulline antibodies appear in the sera they remain
detectable irrespective of the disease status. Between the
two samples the specificities were mainly widening but
some fluctuation was seen in a few patients. A weakness of
our study is that all samples had been collected in early RA
(within a year from diagnosis) and no definite conclusions
about long term variation between antibody titer can be
drawn. In any case, it is worth noticing that the level of
antibodies against homocitrulline-containing antigens in
the 38 hemodialysis patient sera was comparable with that
of healthy controls (data not shown).
Shi and others have previously found 45% of RA pa-
tients to be positive for IgG antibodies that recognize
carbamylated protein [24]. The antigen used in this
study was carbamylated fetal calf serum, a mixture ofseveral carbamylated proteins. In the same study [24]
anti-carbamylated protein antibodies were found to be
related to erosive disease in an anti-CCP negative sub-
group of RA patients. In our study, in two of the 42 ero-
sive RA patients, homocitrulline binding antibodies were
detected alone. All other patients were also positive for
citrulline binding antibodies and/or for RF. Recently,
also, in a large cohort study [25] antibodies binding to
carbamylated proteins were mainly detected in ACPA-
positive RA patients. In the present study, we found that
anti-MCV had the strongest association with the devel-
opment of erosive disease, followed by CCP and RF. Our
study agrees with the results obtained by Mathsson and
coworkers that the anti-MCV test is better than the
anti-CCP-test to predict erosive disease [26]. In our
study, combining these two tests did not give any add-
itional value for predicting erosions. The results are in
line with those obtained by van der Linden et al. [27].
The structural homology of two amino acids is a chal-
lenge for the immune system and a predisposing factor
for development of overlapping specificities. In our
study, the homocitrulline-containing sequences have no
match in the human body, but the results show us prop-
erties of the binding antibodies. It is most probable that
the level of cross-reacting antibodies is dependent on se-
quence homology of the neighboring amino acids in the
immunogen and by analyzing with unnatural sequences
it is not possible to directly identify the real target of
these antibodies.
Our study does not reveal the original immunogen for
anti-citrulline or anti-homocitrulline antibodies. The
homocitrulline-containing type I and II collagen carboxy-
terminal telopeptides used in this study cannot be original
immunogens, because the sequences we used do not exist
in the body. However, the fact that homocitrulline-binding
antibodies mainly exist in individuals showing binding in
anti-CCP and anti-MCV assays suggests that some rela-
tionship between anti-homocitrulline and anti-citrulline
antibodies exist.
At least one situation is known where citrullination
and carbamylation are present together. NETs contain
both hypercitrullinated histones and myeloperoxidase. In
addition, in smokers the thiocynate released from
tobacco smoke favors carbamylation. Thus, NETs in the
oral cavity or in synovial tissue may be the place for
the coexistence citrullination and carbamylation where
the antibodies with overlapping specificities could also
have a role in the development of chronic inflammation.
Conclusions
Antibodies to both citrulline- and homocitrulline-
containing sequences related to type I and II collagen
telopeptides can be found in sera of RA patients. These
antibodies are not constant from one RA patient to
Turunen et al. Arthritis Research & Therapy  (2015) 17:2 Page 6 of 7another, but contain separate or overlapping specific-
ities within the same peptide sequence varying between
individuals. Our results suggest a relationship between
anti-citrulline and anti-homocitrulline antibodies, since
anti-homocitrulline antibodies were found to exist
mainly in individuals seropositive to anti-CCP and anti-
MCV.
Additional file
Additional file 1: Patient data. This file contains RA patients’ primary
Anti-CCP and Anti-MCV-ELISA results and inhibition results of the collagen
telopeptide assays.
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